10-Q: Nkarta Narrows Focus to Autoimmune, Reports Reduced Losses

Nkarta, Inc. reported a strategic pivot to focus on autoimmune disease therapies, reducing operating losses and detailing clinical progress for its lead candidate NKX019, while acknowledging ongoing capital needs.

Summary

• Nkarta, Inc. is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies, primarily focusing on autoimmune diseases.
• The company reported a net loss of $21.7 million for the three months ended September 30, 2025, an improvement from a $28.3 million net loss in the same period of 2024.
• For the nine months ended September 30, 2025, the net loss was $76.7 million, compared to $82.9 million for the nine months ended September 30, 2024.
• Research and development expenses decreased to $20.2 million for the three months and $65.1 million for the nine months ended September 30, 2025, down from $25.3 million and $73.6 million respectively in 2024.
• General and administrative expenses decreased to $7.1 million for the three months ended September 30, 2025, but increased to $25.9 million for the nine months, primarily due to $5.0 million in severance expenses from a March 2025 workforce reduction.
• Cash, cash equivalents, restricted cash, and investments totaled $316.5 million as of September 30, 2025.
• The company believes its current financial resources are sufficient to fund operations for at least 12 months from the filing date.
• A workforce reduction in March 2025 eliminated 53 positions (approximately 34% of the workforce), incurring $5.4 million in severance and benefits costs.
• Nkarta received $1.7 million in Employee Retention Credit (ERC) payments, including interest, in Q3 2025, recognized as $1.5 million in other income and $0.2 million in interest income.
• An impairment charge of $0.8 million related to a right-of-use asset was recorded in Q3 2025 due to a sustained decline in the common stock's trading price.
• The company has deprioritized further development of NKX070, NK+T, and NKX019 for B-cell malignancies to focus resources on NKX019 for autoimmune diseases.
• Clinical trials for NKX019 in autoimmune diseases (Ntrust-1 for lupus nephritis and primary membranous nephropathy; Ntrust-2 for systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis) are ongoing.
• Deep B-cell depletion was observed in patients treated with modified lymphodepleting conditioning (Flu and Cy) in NKX019 autoimmune trials, compared to partial depletion with Cy alone.
• A streamlined enrollment process for Ntrust-1 and Ntrust-2, with combined independent Data Safety Monitoring Board (iDSMB) review, has been implemented, and the iDSMB authorized the second dose-escalation cohort.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to reduced losses, improved operational cash burn, and promising early clinical data for the lead autoimmune program. However, significant accumulated losses, ongoing capital needs, an impairment charge, and deprioritized programs temper the overall outlook, indicating continued high risk inherent in clinical-stage biotech.

Positives

• Net loss significantly decreased for both the three-month ($21.7 million vs. $28.3 million) and nine-month ($76.7 million vs. $82.9 million) periods ended September 30, 2025, compared to 2024.
• Operating expenses decreased by $6.5 million for the three months and $6.2 million for the nine months ended September 30, 2025, reflecting cost containment measures.
• Cash used in operating activities decreased to $67.1 million for the nine months ended September 30, 2025, from $74.9 million in the prior year, indicating improved operational cash burn.
• The company received $1.7 million in Employee Retention Credit payments in Q3 2025, boosting other income.
• Positive clinical data for NKX019 in autoimmune diseases, showing deep B-cell depletion with Flu and Cy lymphodepleting conditioning, supports the strategic shift.
• The iDSMB authorized the initiation of the second dose-escalation cohort for NKX019 in autoimmune trials, indicating clinical progress and safety at initial doses.
• The company has sufficient cash, cash equivalents, restricted cash, and investments ($316.5 million) to fund operations for at least the next 12 months.

Negatives

• The company continues to incur significant net operating losses, with an accumulated deficit of $620.9 million as of September 30, 2025.
• Total assets and stockholders' equity decreased from December 31, 2024, to September 30, 2025, reflecting ongoing losses and asset utilization.
• Interest income decreased for both the three-month and nine-month periods, primarily due to lower average investment balances and interest rates.
• A $0.8 million impairment charge was recognized on a right-of-use asset in Q3 2025, triggered by a sustained decline in the company's stock price.
• The company deprioritized NKX070, NK+T, and NKX019 for B-cell malignancies, indicating setbacks or strategic shifts away from these programs.
• The CRISPR collaboration for NKX070 was terminated by CRISPR, although Nkarta retains a license, the program is deprioritized.
• Significant enrollment challenges have been experienced in the Ntrust-1 and Ntrust-2 clinical trials, which could delay development timelines.

Risks

• Limited operating history and no products approved for sale, leading to speculative investment.
• Expectation of continued significant losses for the foreseeable future and no guarantee of achieving or maintaining profitability.
• Requirement for additional capital, which may cause dilution to stockholders, restrict operations, or necessitate relinquishing rights to product candidates.
• Business highly dependent on the success of the novel CAR NK-cell technology platform, which faces significant development, commercialization, and manufacturing challenges.
• Clinical development is a lengthy, expensive process with uncertain outcomes and potential for substantial delays due to factors outside the company's control.
• Limited clinical data supporting the effectiveness of CD19-targeted cell therapies against autoimmune diseases, and NKX019 may not provide the same therapeutic benefit or be competitive.
• Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be delayed or made impossible by multiple factors.
• Certain aspects of CAR NK cell function and production are unknown or poorly understood, potentially requiring re-engineering, delays, and additional expenses.
• Results of preclinical studies and early-stage clinical trials may not be predictive of future results, and interim data may differ materially from final data.
• Demonstration of relevant, serious adverse events by any product candidate (company's or competitors') could halt or delay further clinical development.
• Failure to compete effectively with academic institutions and other biopharmaceutical companies developing similar or alternative cellular immunotherapy product candidates.
• Manufacturing process is novel and complex, with potential difficulties in production or internal manufacturing leading to supply delays.
• Reliance on a sole supplier (Miltenyi) for certain critical manufacturing steps and reagents, posing supply chain risks.
• Delays in commissioning and receiving regulatory approvals for manufacturing facilities could delay development plans.
• Optimal donor and manufacturing parameters for product candidates have not been definitively established, hindering optimization and addressing safety/efficacy issues.
• Termination of the license agreement with National University of Singapore and St. Jude Childrens Research Hospital, Inc. could lead to loss of rights to key components.
• Inadequate patent protection could allow competitors to develop and commercialize similar products.
• Claims for infringing, misappropriating, or violating third-party intellectual property rights could be costly and delay commercialization.
• Failure to develop or secure marketing, sales, and distribution capabilities would prevent successful commercialization of approved products.
• Product candidates could be subject to regulatory limitations following approval.
• Market price for common stock may be volatile, leading to potential loss of investment.
• Concentration of ownership among existing executive officers, directors, and principal stockholders may prevent new investors from influencing significant corporate decisions.
• Computer system interruptions or security breaches could disrupt product development and business operations.
• Misuse of artificial intelligence could adversely impact the business, including security risks to confidential information.
• Macroeconomic conditions, including rising inflation, interest rates, and supply chain constraints, could adversely affect the business.
• Potential product liability lawsuits could cause substantial liabilities and limit commercialization.
• Inadequate insurance policies may expose the company to unrecoverable risks.
• Failure to address evolving environmental, social, and corporate governance (ESG) matters could negatively impact reputation and business.
• The U.S. government could exercise certain rights in technology developed under government-funded research (Bayh-Dole Act), potentially eliminating exclusive use.
• Uncertainty regarding insurance coverage and reimbursement status of newly approved products could limit marketability.
• Healthcare reform initiatives and other administrative and legislative proposals may harm the business.
• Difficulty in obtaining and maintaining marketing approval or commercialization in multiple jurisdictions.
• Business operations and relationships subject to fraud and abuse and other healthcare laws and regulations, potentially leading to penalties.
• Failure to comply with evolving global privacy laws (e.g., HIPAA, CCPA, CPRA, GDPR) could lead to fines and legal liability.
• Potential for securities class action litigation.
• Impact of securities analysts' reports on stock price.
• Significant increased costs and management time required for operating as a public company and complying with regulations like Sarbanes-Oxley Act Section 404.
• Limitations on the ability to use net operating loss carryovers and certain other tax attributes.
• No expectation of cash dividends to common stockholders for the foreseeable future.
• Anti-takeover effects of corporate governance provisions and Delaware law.
• Forum selection clause could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

Nkarta expects operating expenses to significantly increase as it continues to develop and seek regulatory approvals for product candidates, expand its pipeline, maintain intellectual property, and establish commercial capabilities. The company intends to raise additional capital through equity or debt financings or other arrangements to fund operations until it can generate sufficient revenues. Future funding requirements depend on clinical development pace and results, market conditions, and the success of cost-containment measures. The company believes current cash and investments are sufficient for at least 12 months from the filing date.

Management Comments

• Management plans to continue to incur substantial costs in order to conduct research and development activities for which additional capital will be needed.
• Management believes that the Company's current cash, cash equivalents, restricted cash and investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve months from the filing date of this report.
• The company undertook the Reduction to decrease its costs and create a more streamlined organization to focus on upcoming clinical data updates.
• We believe that engineered NK cells have the potential to be effective and accessible therapies for autoimmune diseases and other diseases, be well tolerated, and avoid some of the toxicities observed with other cell therapies.
• We have funded our operations primarily through the issuance of Company stock and intend to raise additional capital to fund operations until such time that we are able to generate sufficient revenues to cover our operating expenses.

Industry Context

Nkarta operates in the highly competitive clinical-stage biopharmaceutical sector, specifically pioneering allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. This approach is novel, particularly for autoimmune diseases, where no cell-based therapies have yet received FDA approval. The company's strategic shift from oncology to autoimmune diseases positions it in a rapidly evolving therapeutic area with significant unmet medical needs but also intense competition from other cell therapy companies and those developing alternative CD19-targeted therapeutics. The industry faces challenges in patient enrollment, manufacturing complexity, and regulatory precedents for novel cell therapies, alongside increasing scrutiny on drug pricing and healthcare costs.

Comparison to Industry Standards

• Nkarta's focus on allogeneic, off-the-shelf CAR NK cell therapies for autoimmune diseases is a cutting-edge approach, differentiating it from autologous CAR T-cell therapies (e.g., Novartis' Kymriah, Gilead's Yescarta) which are patient-specific and have higher manufacturing complexity and turnaround times.
• While CAR T-cell therapies have shown success in hematologic malignancies, their application in autoimmune diseases is newer, with limited clinical data. Nkarta's NKX019 is in Phase 1 trials for autoimmune indications, similar to other companies exploring CD19-targeted therapies for autoimmune diseases, such as certain academic groups and biopharmaceutical companies like Kyverna Therapeutics (KYV-101, a CD19 CAR T-cell therapy in trials for autoimmune diseases) or Sana Biotechnology (SC291, an allogeneic CD19 CAR T-cell therapy).
• The observed deep B-cell depletion with Flu and Cy lymphodepleting conditioning for NKX019 aligns with the mechanism of action seen in successful CD19-targeted cell therapies in oncology, suggesting potential for efficacy in B-cell mediated autoimmune diseases, but direct comparisons to approved autoimmune treatments (e.g., biologics like rituximab, belimumab) are premature given the early clinical stage.
• The company's accumulated deficit of $620.9 million and ongoing net losses are typical for a clinical-stage biotech company investing heavily in R&D, but the need for substantial additional funding is a common industry challenge, especially for companies without revenue-generating products.
• The workforce reduction and deprioritization of certain programs reflect a common industry practice for early-stage biotechs to conserve capital and focus on lead assets with the highest probability of success, particularly in response to clinical data or market dynamics.

Legal Proceedings

• No claims or actions pending against the company that are likely to have a material adverse effect on its business, results of operations, financial condition, or growth prospects.

Stakeholder Impact

• **Shareholders:** Potential for dilution from future capital raises, volatility in stock price, and long-term value creation dependent on clinical success and commercialization of NKX019. Reduced losses and strategic focus may be viewed positively, but accumulated deficit and impairment are concerns.
• **Employees:** Workforce reduction in March 2025 (34% of workforce) impacted 53 positions, leading to severance costs but also a more streamlined organization. Retention of remaining key personnel is critical.
• **Customers (Future Patients):** Potential for novel, off-the-shelf NK cell therapies for autoimmune diseases, addressing unmet medical needs. Clinical trial progress offers hope for new treatment options.
• **Creditors/Lenders:** The company's liquidity position is deemed sufficient for 12 months, but ongoing losses and the need for future capital raises present a risk profile typical of a clinical-stage biotech.
• **Suppliers/Partners:** Reliance on a sole supplier for certain manufacturing steps (Miltenyi) poses a risk. Collaboration with CRISPR Therapeutics AG has seen a program deprioritized, impacting that partnership.

Next Steps

• Continue clinical development of NKX019 in Ntrust-1 (Lupus Nephritis and primary membranous nephropathy) and Ntrust-2 (systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis) clinical trials.
• Advance patients into the second dose-escalation cohort for NKX019 in autoimmune trials, following iDSMB authorization.
• Monitor and evaluate the impact of modified lymphodepleting conditioning (Flu and Cy) on clinical outcomes in autoimmune trials.
• Continue to manage expenditures and implement cost-containment measures.
• Seek additional funding through equity offerings, debt financings, or collaborations to support ongoing operations and long-term development strategy.
• Evaluate the full-year impact of the 2025 Reconciliation Act on financial statements for the year ended December 31, 2025.
• Evaluate the presentational effect of ASU 2023-09 and ASU 2024-03 on financial statements and related disclosures.

Key Dates

Recommendation

Nkarta is at a critical juncture, having significantly narrowed its strategic focus to autoimmune diseases with its lead candidate NKX019. The reported reduction in net losses and operational cash burn, coupled with promising early clinical data (deep B-cell depletion with Flu/Cy conditioning) and iDSMB authorization for dose escalation, are positive signals. However, the company still faces substantial risks inherent in clinical-stage biotech, including a large accumulated deficit, the need for significant future capital, and ongoing clinical trial enrollment challenges. The impairment charge and deprioritization of other programs highlight past setbacks. For existing investors, holding the stock allows for observation of further clinical data and progress in securing additional funding, as the autoimmune pivot holds high potential but also high risk. For new investors, the stock remains speculative, warranting a 'hold' until more definitive later-stage clinical data and a clearer path to commercialization emerge.

Keywords

CAR NK cell therapy, autoimmune disease, NKX019, lupus nephritis, primary membranous nephropathy, systemic sclerosis, idiopathic inflammatory myopathy, ANCA-associated vasculitis, biopharmaceutical, clinical-stage, off-the-shelf therapy, cell therapy, immunotherapy, clinical trials, biotechnology, SEC filing, 10-Q, financial results